| Chapter title |
Palbociclib—The First of a New Class of Cell Cycle Inhibitors
|
|---|---|
| Chapter number | 11 |
| Book title |
Small Molecules in Oncology
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
| DOI | 10.1007/978-3-319-91442-8_11 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-991441-1, 978-3-31-991442-8
|
| Authors |
Marcus Schmidt, Martin Sebastian, Schmidt, Marcus, Sebastian, Martin |
| Abstract |
During the last decades, much has been learned about with cyclin-dependent kinases (CDK) playing a pivotal role in the cell cycle regulation. CDK4/6 is the key regulator of the G1-S transition. Palbociclib (PD 0332991, Ibrance®) is the first oral CDK4/6 inhibitor showing a substantially improved median progression-free survival (PFS) in advanced estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer. This PFS prolongation was seen both with letrozole as first-line therapy (24.8 vs. 14.5 months [PALOMA 2]) and with fulvestrant in endocrine pretreated patients (9.2 vs. 3.8 months [PALOMA-3]). The main toxicity is neutropenia due to cell cycle arrest which can be easily managed with dose interruption or dose reduction leading to a favorable safety profile with delayed deterioration of global quality of life (QoL). Palbociclib is approved by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) for ER-positive/HER2-negative advanced breast cancer. Despite the well-understood mode of action of palbociclib, predictive biomarkers are not yet defined. In conclusion, inhibition of CDK4/6 using palbociclib in combination with endocrine therapy is an efficient and well-tolerated treatment option in ER-positive/HER2-negative advanced breast cancer. Ongoing clinical trials are investigating the role of palbociclib in early breast cancer as well as in other types of cancer. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 15% |
| Student > Master | 7 | 13% |
| Student > Ph. D. Student | 7 | 13% |
| Student > Bachelor | 4 | 7% |
| Student > Doctoral Student | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 22 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 22% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 4% |
| Immunology and Microbiology | 1 | 2% |
| Other | 8 | 15% |
| Unknown | 25 | 45% |